May 2024 in “Psychiatric News” In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.
September 2024 in “Journal of the American Academy of Dermatology” This study observed that among patients starting Semaglutide therapy at 0.25-2mg weekly, approximately 0.80-0.83% reported non-scarring hair loss within six months, suggesting the drug does not significantly increase hair loss risk.
September 2026 in “Problems of Endocrinology” This article discusses the prevalence and mechanisms of hair loss associated with weight loss treatments and reports no new clinical results; it emphasizes the need for prevention and management strategies in affected patients.
June 2021 in “Research Square (Research Square)” This study found that despite cosmetic effects from antiepileptic drugs like hair loss and weight gain, Sudanese epilepsy patients generally prioritized medication adherence, potentially influenced by cultural perceptions.
815 citations
,
April 2010 in “The Journal of Clinical Endocrinology & Metabolism” This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.
